SGC-CBP30

Name: SGC-CBP30
Brand: MedChemExpress
SKU: HY-15826
Rating: 5.0 (13 reviews)

Cat. No.: HY-15826 Purity: 99.60%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects.

For research use only. We do not sell to patients.

SGC-CBP30 Chemical Structure

CAS No. : 1613695-14-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 112	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 112	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 77	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 100	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 450	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 760	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

13 Publications Citing Use of MCE SGC-CBP30

•Methods Mol Biol. 2018;1711:351-398. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Acetyltransferase Isoform Specific Products:

View All Isoforms

CBP/p300 GCN5/PCAF TIP60 MOZ/MORF HBO1

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

CBP/p300

Cellular Effect

Cell Line	Type	Value	Description	References
CWR22R	IC₅₀	> 10 μM Compound: CBP30	Antiproliferative activity against human 22Rv1 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human 22Rv1 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]
HEK293	IC₅₀	2.8 μM Compound: 2; SGC-CBP30	Inhibition of Halo-tagged histone H3.3 binding to NanoLuc luciferase conjugated CBP (unknown origin) expressed in HEK293 cells after overnight incubation by BRET assay Inhibition of Halo-tagged histone H3.3 binding to NanoLuc luciferase conjugated CBP (unknown origin) expressed in HEK293 cells after overnight incubation by BRET assay	[PMID: 27682507]
MCF7	IC₅₀	2.39 μM Compound: CBP30	Antiproliferative activity against human MCF7 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human MCF7 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]
MOLM-13	IC₅₀	1.53 μM Compound: CBP30	Cytotoxicity against human MOLM-13 cells assessed as cell growth inhibition incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human MOLM-13 cells assessed as cell growth inhibition incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 33872011]
OPM-2	IC₅₀	2.64 μM Compound: CBP30	Antiproliferative activity against human OPM-2 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human OPM-2 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]
RKO	IC₅₀	1.5 μM Compound: 11; SGC-CBP30	Inhibition of doxorubicin-stimulated p53 (unknown origin) expressed in human RKO cells preincubated for 24 hrs followed by addition of doxorubicin for 16 hrs by luciferase reporter assay Inhibition of doxorubicin-stimulated p53 (unknown origin) expressed in human RKO cells preincubated for 24 hrs followed by addition of doxorubicin for 16 hrs by luciferase reporter assay	[PMID: 26572217]
SCC-9	IC₅₀	6.42 μM Compound: CBP30	Antiproliferative activity against human SCC-9 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human SCC-9 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]

In Vitro

In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 inhibits IL-17A secretion by Th17 cells. Transcriptional profiling of human T cells after SGC-CBP30 treatment shows a much more restricted effect on gene expression than that observed with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SGC-CBP30 treatment slightly alleviates alveolar bronchial fibrosis induced by NSC-125066. SGC-CBP30 plus CQ-061 dramatically reduces alveolar bronchial fibrosis. The ELISA of cytokines IL-4 and IFN-γ in BALF demonstrates that combination of SGC-CBP300 and CQ-061 suppresses the activation of IL-4 as well as IFN-γ in NSC-125066 induced IPF murine models to nearly normal levels^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066^[2]
Dosage:	25 mg/kg
Administration:	Oral administration; daily; for 14 days
Result:	Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

Molecular Weight

509.04

Formula

C₂₈H₃₃ClN₄O₃

CAS No.

1613695-14-9

Appearance

Solid

Color

Off-white to yellow

SMILES

C[C@H](N1CCOCC1)CN2C(CCC3=CC=C(OC)C(Cl)=C3)=NC4=CC(C5=C(C)ON=C5C)=CC=C42

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 66.67 mg/mL (130.97 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9645 mL	9.8224 mL	19.6448 mL
5 mM	0.3929 mL	1.9645 mL	3.9290 mL
10 mM	0.1964 mL	0.9822 mL	1.9645 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.83%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (251 KB) LCMS (137 KB)

Handling Instructions (2659 KB)

References

[1]. Hammitzsch A, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73. [Content Brief]

[2]. Tao J, Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomed Pharmacother. 2018 Oct;106:1727-1733. [Content Brief]

[3]. Hay DA, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc. 2014 Jul 2;136(26):9308-19. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9645 mL	9.8224 mL	19.6448 mL	49.1121 mL
	5 mM	0.3929 mL	1.9645 mL	3.9290 mL	9.8224 mL
	10 mM	0.1964 mL	0.9822 mL	1.9645 mL	4.9112 mL
	15 mM	0.1310 mL	0.6548 mL	1.3097 mL	3.2741 mL
	20 mM	0.0982 mL	0.4911 mL	0.9822 mL	2.4556 mL
	25 mM	0.0786 mL	0.3929 mL	0.7858 mL	1.9645 mL
	30 mM	0.0655 mL	0.3274 mL	0.6548 mL	1.6371 mL
	40 mM	0.0491 mL	0.2456 mL	0.4911 mL	1.2278 mL
	50 mM	0.0393 mL	0.1964 mL	0.3929 mL	0.9822 mL
	60 mM	0.0327 mL	0.1637 mL	0.3274 mL	0.8185 mL
	80 mM	0.0246 mL	0.1228 mL	0.2456 mL	0.6139 mL
	100 mM	0.0196 mL	0.0982 mL	0.1964 mL	0.4911 mL

SGC-CBP30 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SGC-CBP301613695-14-9Epigenetic Reader DomainHistone AcetyltransferaseHATsHATBRDankylosingspondylitispsoriaticarthritisTh17cellsIL-17Aanti-inflammatoryepigeneticInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

SGC-CBP30

Customer Review

SGC-CBP30 Related Antibodies

13 Publications Citing Use of MCE SGC-CBP30

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Acetyltransferase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

SGC-CBP30 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

SGC-CBP30 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report